Zejing Biopharma develops both chemical and biological new drugs with a focus on oncology; its lead candidate is donafenib, a multikinase inhibitor undergoing late-stage studies. The company has advanced donafenib into multiple indications, including first-line advanced hepatocellular carcinoma and trials in colorectal, thyroid, nasopharyngeal and gastric cancers. It operates an expanding pipeline with more than a dozen clinical programs across chemical and biologic assets. The company has completed GMP facilities for solid formulations and recombinant protein products and obtained an oral solid formulation production license in 2017. Management planned to secure a recombinant protein production license in the first half of 2018 to support commercial manufacturing. The recent financing supports late-stage clinical development, pre-commercial production preparation and general operations.

Total raised

$62M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2018